Objectives The efficacy of a novel vaccine against influenza virus A (H 1 N 1) in patients with
hematologic malignancies is largely unknown. Methods We prospectively evaluated the …

Patients with hematological malignancies are at increased risk of influenza and its
complications, but evidence for the efficacy of influenza vaccination in this population is …

Background Patients with hematological malignancies are more susceptible to viral
infections including influenza. In 2009, the W orld H ealth O rganization classified the novel …

Patients with hematological malignancies have high risk for morbidity and mortality from
influenza. This study was conducted to evaluate the immunogenicity and reactogenicity of …

This is a randomized trial evaluating the safety and immunogenicity of one or two doses of
2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies. Adults …

Abstract Learning Objectives After completing this course, the reader will be able to: Cite the
primary concerns of oncologists regarding influenza vaccination for their cancer patients …

Background Cancer patients often experience preventable infections, including influenza A
and B. These infections can be a cause of significant morbidity and mortality. The increased …

Background In 2009 the declaration by the World Health Organization of a global pandemic
of influenza-H1N1 virus led to a vaccination campaign to ensure protection for …

Seroconversion rates following influenza vaccination in patients with hematologic
malignancies after hematopoietic stem cell transplantation (HSCT) are known to be lower …

BACKGROUND: Patients with hematologic malignancies are at increased risk of influenza
and its complications. Despite current health recommendations and evidence favoring …